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Abstract 
Background: Stevens-Johnson Syndrome (SJS) is a rare but potentially life-
threatening form of Severe Cutaneous Adverse Reaction (SCAR). SJS is mostly 
caused by drugs and is associated with high morbidity and mortality. Moreover, 
no standard treatment has been established for SJS. The aim of this study is to 
present epidemiological features, etiologies, clinical outcomes, medical histories, 
and treatments of SJS patients at the Inpatient Units Kemuning I and II Dr. 
Soetomo General Hospital between 2011 until 2015.  
Methods: This retrospective study used secondary data collected from medical 
records. All patients in the Inpatient Units Kemuning I and II of Dr. Soetomo 
General Hospital from the year 2011 until 2015 who was diagnosed SJS were 
included in this study.  
Result: There were 29 medical records consisting of 23 females and 6 males with 
the diagnosis of SJS found in 2011-2015. Most patients were aged 25-44 years 
old, with no family history of SJS. A majority first presented with a clinical 
history of fever. The main cause of SJS in this cohort was amoxicillin. Mucosal 
areas that were involved the most was the eye and mouth. Systemic treatments 
for patients were corticosteroid. The average duration of treatment was 15,88 
days. None of the patients died.  
Conclusion: SJS was more common in females compared to males. The main 
systemic therapy in Inpatient Units Kemuning I dan II of Dr. Soetomo General 
Hospital was intravenous cortiosteroid and no patients died. 
 
 
INTRODUCTION 
Stevens-Johnson Syndrome (SJS) is a rare Severe 
Cutaneous Adverse Reaction (SCAR) 
characterized by erythematous macules evolving 
to epidermal detachment and mucosa membrane 
erosions.1 The involvement of at least two 
mucosal membranes are required for establishing 
the diagnosis of SJS.2 In SJS there is less than 10% 
body surface area involved. Meanwhile, Toxic 
Epidermal Necrolysis (TEN) has the exact same 
clinical features with SJS, but with  
 
 
involvement of more than 30% body surface 
area.3 Incidence of SJS was reported to vary from 
1.2 to 6 per million patient per year and is a major 
concern due to its severe morbidity and mortality.  
Although the mechanism of SJS is still unclear, it 
is mostly associated with the use of certain drugs. 
 
Other possible causes of SJS are infections, 
immunizations, environmental chemicals and 
radiation therapy. Drugs that commonly caused 
SJS include antibiotics, anti-convulsants, non-
steroidal anti-inflammatory drugs (NSAIDS) and 
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allopurinol.4 Risk of SJS increases in patients with 
HIV, collagen vascular disease, and cancer. 
 
Clinical symptoms vary among patients. The 
syndrome usually begins with the prodromal 
symptoms of fever, headache and myalgia.5 SJS 
lesions first appear erythematous then evolve into 
dusky or purpuric macules. The lesions usually 
have irregular shapes, discrete in the beginning 
then coalesce with one another.3 Early sites of 
cutaneous involvement are not limited to the trunk 
and the face, and often involve the palms and 
soles. More than 90% of patients have an 
involvement on the buccal, genital and or ocular 
mucosa. Some cases also involved the respiratory 
and gastrointestinal mucosa.6 
 
Sepsis is the most common complication of SJS 
and the most common cause of patient death. Skin 
erosion leads to easier bacterial infection hence 
which leads to many complications. Genital 
erosions also can cause dyspareunia.2,6  
Score for Toxic Epidermal Necrolysis 
(SCORTEN) is a scale used for measuring level 
of severity from epidermal necrolysis. 
SCORTEN’s function is for determining 
prognosis of SJS.3,6 History of the patient’s 
disease, such as HIV, tuberculosis or diabetes also 
has an impact on prognosis, for example. If patient 
has history said diseases, then SCORTEN’s score 
is 5 or more than 5.4 
 
Table 1. SCORTEN 
Parameter Points 
Age > 40 year 1 
Blood Pressure >120/min 1 
Cancer/Malignancy 1 
>10% Body Surface Area 1 
Serum Urea >10mm/L 1 
Serum Bicarbonate 
<20mmL 
1 
Serum Glucose >14mm/L 1 
 
Points Mortality Rate 
1 3,20% 
2 12,10% 
3 35,50% 
4 58,30% 
>5 90,00% 
Adapted from Ho,2008 
 
METHODS 
This is a retrospective study which used secondary 
data collected from the medical records. 
Instruments used are medical records of patients 
diagnosed with SJS in Inpatient Units Kemuning 
I and II Dr. Soetomo Regional Hospital in 2011-
2015. Data obtained includes the age, gender, 
aetiology, medical history, inciting medications, 
clinical features, and family history. The 
treatment-regimens, length-of-stay, and mortality 
were also recorded.  
 
RESULTS 
The total number of patients that were 
hospitalized in Inpatient Units Kemuning I and II 
Dr. Soetomo General Hospital were 1750 during 
the study period of 2011-2015. Among these, 29 
SJS cases were found. There were 5 (1,09%) cases 
in 2011, 4 cases in 2012 (0,95%), 5 cases in 2013 
(1,1%), 4 cases in 2014 (1,5%), and 11 cases in 
2015 5,5%). There were 22 (75,8%) females and 
7 males (24,14%).  
 
According to data from Inpatient Units Kemuning 
I and II from 2011-2015, the mean patient age was 
36,58 years. Most patients diagnosed with SJS 
were in the 25-44 years old range with a total of 
12 (41,37%) patients. The second most prevalent 
age group was 45-64 years old (34,48%) with a 
total of 10 patients, and third was 15-24 years old 
with a total of 7 patients (24,13%).  
  
Patient history prior to SJS occurrence showed 
fever as the most common history which was 
present in 6 patients (20%), followed by epilepsy 
in 5 patients (16,67%). Other history of disease 
before the occurrence of SJS are Low Back Pain 
(3,33%), Systemic Lupus Erythematosus (3,33%), 
Common Cold (6,66%), Post Op Trepanation 
(3,33%), Headache (3,33%), Brain Tumor 
(3,33%), Post Op Kidney Stones (3,33%), 
Terminal Neuralgia (3,33%), and Convulsions 
(3,33%). 
 
History of drug use in SJS patients revealed the 
most common eliciting drug as antibiotics 
followed by anti-epileptic medication (Table 2). 
However, since patients mostly consumed more 
than one drug, it is difficult to precisely determine 
which drug caused the SJS. Patients also had 
history of using herbal medicine. 
 
The main systemic therapy given to patients were 
glucocorticoids, such as oral methylprednisolone 
80-120 mg at 1.5-2 mg/kg/day or intravenous 
dexamethasone at 0.15-0.2 mg/kg/day. As much 
as 23 patients (79,31%) were treated with 
intravenous dexamethasone 3x2 mg/day, 2 
patients (6,89%) were treated with intravenous 
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dexamethasone 2x4 mg/day, 2 patients (6,89%) 
were treated with oral dexamethasone 1.5-
2mg/kg/day, and 2 patients (6,89%) were treated 
with oral methylprednisolone 80-120 mg. Patients 
also received antibiotic therapy. As much as 14 
patients (48,27%) received intravenous 
gentamycin at 2x80 mg iv/day, 9 patients 
(31,03%) received cefotaxime 3x1 gram iv/day, 2 
patients (6,89%) received ceftriaxone 2x1 gram 
iv/day, 3 patients (10,34%) received oral 
erythromycin 3x500 gram, and 1 patient (3,44%) 
received oral amoxicillin 3x500 gram.   
  
Mucosal involvement in SJS patient occured in 
buccal (20,68%), genital and eyes (3,44%), 
genital and buccal (10,34%), eyes and buccal 
(31,03%), and genital, buccal, and eyes (27,58%). 
The buccal area was the most common mucosal 
area involved in SJS.  
 
Sepsis (3,44%), symblepharon (6,89%), and acute 
kidney injury (6,89%) occurred in patients as the 
complication of SJS. The average duration of stay 
was 15,68 days. From this study, we found no 
patients died because of SJS. 
 
Table 2. History of drugs consumed before SJS 
occurrence by SJS inpatients at Units Kemuning I 
and II of Dr. Soetomo General Hospital. 
 
No History of Drug Use Total (%) 
1. Antibiotic 25 (43) 
 Sulfamethoxazole  1 (1,75) 
 Tiamphenicol 3 (5,26) 
 Cefadroxil 5 (8,77) 
 Amoxicilin 6 (10,52) 
 Levofloxacin 3 (5,26) 
 Ceftriaxone 2 (3,50) 
 Ciprofloxacin 2 (3,50) 
 Cefixime 3 (5,26) 
2. Anti-epileptics 10 (17,54) 
 Carbamazepine 5 (8,77) 
 Phenytoin 4 (7,01) 
 Valproic Acid 1 (1,75) 
3. Analgesic 17 (31,48) 
 Paracetamol 13 (22,80) 
 Salicylic Acid 1 (1,75) 
 Piracetam 1 (1,75) 
 Tinoridine 1 (1,75) 
 Mefenamic acid 2 (3,50) 
4. Antidepressants 1 (1,75) 
 Amitriptyline 1 (1,75) 
5. Allopurinol 3 (5,26) 
6. Acyclovir 1 (1,75) 
7.  Jamu (herbal 
medicine) 
3 (10,52) 
Total  57 (100) 
*) Patients can use >1 drug 
Source: Secondary Data 
DISCUSSION 
The 5-year incidence of SJS in Inpatient Units 
Kemuning I and II is 1,65%. This is similar to the 
incidence range in RSUD Dr. Moewardi Surakarta 
from August 2011–2013, at 2,93%–3,30%. The 
most common age range in SJS patient is 25-44 
year. The average in patients’ age is 36,58 year 
with standard deviasion 14,23.11 The number of 
females diagnosed was greater than males. This is 
in line with the study by Allanore and Roujeau 
which found that females have higher risk of SJS.2 
 
According to Clinical Practice Guidelines SMF 
Dermatovenerology of Dr. Soetomo Regional 
Hospital,7 management of SJS need to be 
performed in specialized rooms. However due to 
room limitations, patients were not transferred to 
the room. According to studies by Kim et al and 
Yim et al, SJS patients who are treated in burn 
intensive care units showed faster reepithelization 
time of the SJS skin lesion.8,9 Stopping the 
medication that caused SJS is also an important 
thing that impacts treatments success,3 as 
morbidity and mortality will increase when drug 
discontinuation is delayed.10 
 
Correction of fluid balance, electrolyte, and 
protein was performed in all patients. Patient 
treatment also included control of the body 
temperature and provision of adequate nutrition. 
Patients were mainly treated with corticosteroids. 
The use of corticosteroid depends on country use. 
Germany also uses corticosteroid as the main 
therapy, while in France, corticosteroid is used as 
the main therapy only in a quarter of patients. The 
maximum corticosteroid dosage allowed is 250 
mg in Germany and 75 mg in France.  Level of 
treatment success by using corticosteroid in 
Germany is 59% and in France is 27% .1 In a study 
from Tan and Tay4 corticosteroid was used in 16 
out of 18 SJS patients. No patients experienced 
complications. The study stated that corticosteroid 
use is better given before tissue damage or further 
phases.4 
 
According to that study, antibiotics were used if 
indications were clear.4 But in this study, we 
found that antibiotics were used because no 
patients were treated in a special room. It 
increases the risk of infection in the patient if they 
were not given antibiotics. All patients were given 
high-calorie and high-protein nutrition during 
their stay.  
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Patients with a history of epilepsy have a high 
incidence of SJS because due to the consumption 
of anti-epileptics, which has been highly 
associated with risk of SJS. Anti-epileptic drugs 
with the high SJS risk include carbamazepine, 
phenobarbital, and phenytoin.2 From the five 
epilepsy patients, three patients consumed 
carbamazepine, and one patient consumed 
phenytoin. 
 
According to Allanore and Roujeau,2 other drugs 
with high SJS risk include allopurinol, 
sulfamethoxazole, sulfadiazine, sulphapyridine, 
sulfadoxine, sulfasalazine, carbamazepine, 
lamotrigine, phenobarbital, phenytoin, 
phenylbutazone, nevirapine, oxicam Nonsteroidal 
Anti-Inflammatory Drug (NSAID), and 
thioacetazone. Drugs with low risk for causing 
SJS are diclofenac, aminopenicillin, 
cephalosporin, quinolones, cyclin, and macrolide. 
Three patients consumed jamu herbal medicine 
before the occurrence of SJS. Jamu is a 
concoction of herbs such as roots, leaves, etc. 
Indonesians prefer consuming jamu to reduce 
pain. According to a study on 10 jamu herbal 
medicine samples performed in Surakarta,12 two 
contained diclofenac sodium and two contained 
phenylbutazone. So, it does not rule out the 
possibility that SJS patients who consumed herbs 
also consumed sodium diclofenac, 
phenylbutazone or other drugs in the category.  
 
There was no family history of SJS in this cohort 
of patients, and there were no racial or ethnic 
connections between drugs which trigger SJS 
reaction. Previous studies have shown 
associations between HLA-B*15:02 and 
carbamazepine-induced SJS in the Han Chinese, 
Thailand, Indian, and Malaysian population. 
Relationship between HLA B*58:01 with 
allopurinol-induced SJS is also present in the 
European, Japanese, Han Chinese, and Thai 
populations. This has been the basis of 
recommendations for physicians to be more 
cautious when prescribing certain drugs to some 
ethnicities.4 
 
The average length of stay was 15,68 days with a 
standard deviation of 5,84. The longest period of 
hospitalization was 26 days and the shortest 
duration of hospitalization was 4 days. The patient 
discharged in the fourth day did so due to his 
parents’ wishes. Two patients were discharged 
after 26 days in hospital because they had a bad 
condition. One of them has the increased serum 
transaminase until 491 U/dl.  
 
There were no patients who died in this cohort. A 
study from Mockenhaupt13 in Germany showed 
that SJS mortality ranges from 5% until 12%. The 
study from Tan and Tay4 also showed there were 
no patients who died because of SJS In August 
2011– August 2013, there were no patients that 
died because of SJS in RSUD Dr. Moewardi 
Surakarta.11 
 
CONCLUSION 
Early diagnosis and identification of medications 
that cause SJS is very important. Early 
discontinuation of the eliciting drug and provision 
of the correct treatment is key for mortality 
reduction. In this study there were 29 SJS cases 
which were mostly elicited by medications. No 
patients in this cohort died, and the main therapy 
used was corticosteroid.  
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